Northern Trust Corp Lineage Cell Therapeutics, Inc. Transaction History
Northern Trust Corp
- $658 Billion
- Q1 2025
A detailed history of Northern Trust Corp transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,539,586 shares of LCTX stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,539,586
Previous 1,274,492
20.8%
Holding current value
$1.74 Million
Previous $637,000
8.63%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding LCTX
# of Institutions
138Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$56 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$10.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$10.1 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$7.13 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$6.38 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $192M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...